Skip to content
Recall Observatory FDA recall evidence

Drug product

Viokace (pancrelipase) tablets, 20,880 USP units, 100-count bottle, Rx only, Distributed by; Allergan USA Inc., Irvine, CA 92612, Manufactured in Canada, NDC 58914-117-10

D-0154-2018

December 04, 2017

Class II

Product summary

Firm
ALLERGAN
Event
Event 78652
Status
Terminated
Classification
Class II
Quantity
12,699 bottles
Official record key
drug-enforcement:D-0154-2018

Official wording

Reason: Subpotent Drug: One lot of Viokace is being recalled since product stability testing results did not meet the specifications for enzyme profile.

Code information: Lot #: 160741A, Exp 02/18

Distribution pattern: U.S.A. nationwide

Derived failure modes

  • Potency or specification failure

    reason.potency_specification_failure · v1.0.0

    Subpotent